SELECT FROM MENU

Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immuno-therapies

Antibody Drug Conjugates

Antibody-Drug Conjugates

2025 Approvals & Highlights

2025 Approvals & Highlights

UPCOMING Join us forour roundtable in||latest advances in||your questions on||new therapies for||practice changes in||your patient cases in 2025 Highlights in Lung Cancer Martin Reck Germany Solange Peters Switzerland Agenda & Discussion Topics Current Standards...
Targeted Therapies in NSCLC

Targeted Therapies in NSCLC

Targeted Therapies in NSCLC Current Standards and Challenges in ALK+ and EGFR+ NSCLC Oliver Gautschi Unlocking Synergies with Chemo, Bispecifics and TKIs Jarushka Naidoo LATEST ADVANCES IN RECURRENT EGFR+ NSCLC: FOCUS ON MET Nicolas Girard  10 JULY 2025 } 1 h 30 min...
Immunotherapies in NSCLC

Immunotherapies in NSCLC

IO in early stage & combinations in late NSCLC LESS IS MORE – NEOADJUVANT IO ALONE IS UNDOUBTEDLY SUFFICIENT Patrick Forde EMBRACING ADDITIONAL ADJUVANT IO: A CRUCIAL AND NECESSARY ADD-ON Jordi Remon MAXIMIZING OUTCOMES: THE ROLE OF IO COMBINATIONS Solange Peters...

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates